51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00418132 (ClinicalTrials.gov) | August 2000 | 3/1/2007 | Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis | T Cell Immunity in Collagen Biosynthesis of Scleroderma | Scleroderma, Systemic | Drug: Thalidomide;Drug: Placebo thalidomide | New York University School of Medicine | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Terminated | 18 Years | 65 Years | Both | 30 | Phase 1 | United States |